Treatment of Ph+ ALL with the tyrosine kinase inhibitor (TKI) resulted in a decrease in MCL-1 expression, whereas BCL-2 and BCL- XL were not affected. The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.